Gene therapy as future treatment of erectile dysfunction

Expert Opinion on Biological Therapy

Volumn 10, Issue 9, 2010, Pages 1305-1314

  Yoshimura, Naoki ^a   Kato, Ryuichi ^a   Chancellor, Michael B ^b   Nelson, Joel B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Erectile dysfunction; Gene therapy; Growth factor; K+ channel; Nitric oxide

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENOVIRUS VECTOR; ARGINASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEURTURIN; NITRIC OXIDE SYNTHASE INHIBITOR; VASCULOTROPIN;

AGING; BLOOD VESSEL PERMEABILITY; DIABETES MELLITUS; ERECTILE DYSFUNCTION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HYPERCHOLESTEROLEMIA; INTERMETHOD COMPARISON; NERVE GROWTH; NERVE REGENERATION; NERVE STIMULATION; NONHUMAN; PARASYMPATHETIC NERVE CELL; REVIEW; SMOOTH MUSCLE TONE;

ANIMALS; ERECTILE DYSFUNCTION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NITRIC OXIDE; PENILE ERECTION; PENIS; POTASSIUM CHANNELS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77955538510     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.510510     Document Type: Review

References (99)

1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56
2. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(Suppl 4):S6-11
3. Deng W, Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ. Gene and stem cell therapy for erectile dysfunction. Int J Impot Res 2005;17(Suppl 1):S57-63
4. Seftel AD. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003;169:1999-2007
5. Montorsi F, Briganti A, Salonia A, et al. The ageing male and erectile dysfunction. BJU Int 2003;92:516-520
6. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-463
7. Kloner RA. Erectile dysfunction in the cardiac patient. Curr Urol Rep 2003;4:466-471
8. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 2002;4:397-401
9. Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002;2:501-509
10. Burnett AL. Strategies to promote recovery of cavernous nerve function after radical prostatectomy. World J Urol 2003;20:337-342
11. Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000;164:1929-1934
12. Shimizu T, Hisasue S, Sato Y, et al. Erectile dysfunction following nerve-sparing radical retropubic prostatectomy and its treatment with sildenafil. Int J Urol 2005;12:552-557
13. Siroky MB, Azadzoi KM. Vasculogenic erectile dysfunction: newer therapeutic strategies. J Urol 2003;170(2 Pt 2):S24-9; discussion S9-30
14. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001;44:1296-1301
15. Briganti A, Salonia A, Deho F, et al. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. World J Urol 2005;23:374-384 (Pubitemid 43124388)
16. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-426
17. Harraz A, Shindel AW, Lue TF. Emerging gene and stem cell therapies for the treatment of erectile dysfunction. Nat Rev Urol 2010;7:143-152
18. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, non cholinergic neurotransmission. N Engl J Med 1992;326:90-94
19. Burnett AL, Lowenstein CJ, Bredt DS, et al. Nitric oxide: a physiologic mediator of penile erection. Science 1992;257:401-403
20. Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005;106:233-266
21. Feifer A, Carrier S. Pharmacotherapy for erectile dysfunction. Expert Opin Investig Drugs 2008;17:679-690
22. Hung A, Vernet D, Xie Y, et al. Expression of inducible nitric oxide synthase in smooth muscle cells from rat penile corpora cavernosa. J Androl 1995;16:469-481
23. Saenz de Tejada I, Blanco R, Goldstein I, et al. Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue. Am J Physiol 1988;254:H459-67
24. Giuliano F, Rampin O. Neural control of erection. Physiol Behav 2004;83:189-201
25. Garban H, Vernet D, Freedman A, et al. Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol 1995;268:H467-75
26. Matz RL, Andriantsitohaina R. Age-related endothelial dysfunction: potential implications for pharmacotherapy. Drugs Aging 2003;20:527-550
27. Saenz de Tejada I, Goldstein I, Azadzoi K, et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-1030
28. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-1813
29. Champion HC, Bivalacqua TJ, Hyman AL, et al. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 1999;96:11648-11652
30. Bivalacqua TJ, Champion HC, Mehta YS, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 2000;12(Suppl 3):S8-17
31. Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003;169:1911-1917
32. Bivalacqua TJ, Usta MF, Champion HC, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 2004;16:21-29
33. Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1278-90
34. Magee TR, Ferrini M, Garban HJ, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002;67:20-28
35. Garban H, Marquez D, Magee T, et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1997;56:954-963
36. Chancellor MB, Tirney S, Mattes CE, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 2003;91:691-696
37. Magee TR, Ferrini MG, Davila HH, et al. Protein inhibitor of nitric oxide synthase (NOS) and the N-methyl-D-aspartate receptor are expressed in the rat and mouse penile nerves and colocalize with penile neuronal NOS. Biol Reprod 2003;68:478-488
38. Magee TR, Kovanecz I, Davila HH, et al. Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat. J Sex Med 2007;4:633-643
39. Kim NN, Cox JD, Baggio RF, et al. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 2001;40:2678-2688
40. Bivalacqua TJ, Hellstrom WJ. Potential application of gene therapy for the treatment of erectile dysfunction. J Androl 2001;22:183-190
41. Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol 2007;292:H1340-51
42. Hedlund P, Aszodi A, Pfeifer A, et al. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci USA 2000;97:2349-2354
43. Chang S, Hypolite JA, Velez M, et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol 2004;287:R950-60
44. Bivalacqua TJ, Kendirci M, Champion HC, et al. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha. BJU Int 2007;99:1488-1494
45. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999;161:5-11
46. Bemelmans BL, Meuleman EJ, Doesburg WH, et al. Erectile dysfunction in diabetic men: the neurological factor revisited. J Urol 1994;151:884-889
47. Dahiya R, Chui R, Perinchery G, et al. Differential gene expression of growth factors in young and old rat penile tissues is associated with erectile dysfunction. Int J Impot Res 1999;11:201-206
48. Lin G, Chen KC, Hsieh PS, et al. Neurotrophic effects of vascular endothelial growth factor and neurotrophins on cultured major pelvic ganglia. BJU Int 2003;92:631-635
49. Bennett NE, Kim JH, Wolfe DP, et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005;173:1820-1824
50. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997;89:1117-1123
51. Palma CA, Keast J.R. Structural effects and potential changes in growth factor signalling in penis-projecting autonomic neurons after axotomy. BMC Neurosci 2006;7:41
52. Laurikainen A, Hiltunen JO, Vanhatalo S, et al. Glial cell line-derived neurotrophic factor is expressed in penis of adult rat and retrogradely transported in penile parasympathetic and sensory nerves. Cell Tissue Res 2000;302:321-329
53. Markus A, Patel TD, Snider WD. Neurotrophic factors and axonal growth. Curr Opin Neurobiol 2002;12:523-531
54. Wanigasekara Y, Keast J.R. Neurturin has multiple neurotrophic effects on adult rat sacral parasympathetic ganglion neurons. Eur J Neurosci 2005;22:595-604
55. Laurikainen A, Hiltunen JO, Thomas-Crusells J, et al. Neurturin is a neurotrophic factor for penile parasympathetic neurons in adult rat. J Neurobiol 2000;43:198-205
56. Wanigasekara Y, Airaksinen MS, Heuckeroth RO, et al. Neurturin signalling via GFRalpha2 is essential for innervation of glandular but not muscle targets of sacral parasympathetic ganglion neurons. Mol Cell Neurosci 2004;25:288-300
57. Hisasue S, Kato R, Suetomi T, et al. Age-related alteration of neurturin receptor GFRa2 and nNOS in pelvic ganglia. Neurobiol Aging 2006;27:1524-1530
58. Bella AJ, Fandel TM, Tantiwongse K, et al. Neurturin enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J Brachial Plex Peripher Nerve Inj 2007;2:5
59. Kato R, Wolfe D, Coyle CH, et al. Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther 2007;14:1344-1352
60. Kato R, Wolfe D, Coyle CH, et al. Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther 2009;16:26-33
61. Bakircioglu ME, Lin CS, Fan P, et al. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol 2001;165:2103-2109
62. Gholami SS, Rogers R, Chang J, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 2003;169:1577-1581
63. Shirai M, Yamanaka M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat. Biochem Biophys Res Commun 2006;341:755-762
64. Yamanaka M, Shirai M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005;173:318-323
65. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273:13313-13316 (Pubitemid 28246905)
66. DallEra JE, Meacham RB, Mills JN, et al. Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model. Int J Impot Res 2008;20:307-314
67. Ryu JK, Cho CH, Shin HY, et al. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther 2006;13:705-715
68. Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15:26-37
69. Jung GW, Kwak JY, Yoon S, et al. IGF-I and TGF-beta2 have a key role on regeneration of nitric oxide synthase (NOS)-containing nerves after cavernous neurotomy in rats. Int J Impot Res 1999;11:247-259 (Pubitemid 29505064)
70. Bochinski D, Hsieh PS, Nunes L, et al. Effect of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 complex in cavernous nerve cryoablation. Int J Impot Res 2004;16:418-423
71. El-Sakka AI, Lin CS, Chui RM, et al. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res 1999;11:123-132
72. Pu XY, Hu LQ, Wang HP, et al. Improvement in erectile dysfunction after insulin-like growth factor-1 gene therapy in diabetic rats. Asian J Androl 2007;9:83-91
73. Salkoff L, Butler A, Ferreira G, et al. High-conductance potassium channels of the SLO family. Nat Rev Neurosci 2006;7:921-931
74. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236
75. Wei AD, Gutman GA, Aldrich R, et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 2005;57:463-472
76. Spektor M, Rodriguez R, Rosenbaum RS, et al. Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol 2002;167:2628-2635
77. Fan SF, Brink PR, Melman A, Christ GJ. An analysis of the Maxi-K+ (KCa) channel in cultured human corporal smooth muscle cells. J Urol 1995;153:818-825
78. Lau DH, Kommu SS, Siddiqui EJ, et al. Gene therapy and erectile dysfunction: the current status. Asian J Androl 2007;9:8-15
79. Christ GJ, Rehman J, Day N, et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 1998;275:H600-8
80. Christ GJ, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1544-53
81. Melman A, Zhao W, Davies KP, et al. The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 2003;170:285-290
82. Melman A, Biggs G, Davies K, et al. Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat. Gene Ther 2008;15:364-370
83. Christ GJ, Andersson KE, Williams K, et al. Smooth-muscle-specific gene transfer with the human Maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol 2009;52:1055-1066
84. Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006;17:1165-1176
85. Melman A, Bar-Chama N, McCullough A, et al. Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a Phase I trial. Isr Med Assoc J 2007;9:143-146
86. Melman A, Rojas L, Christ G. Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologists? Curr Opin Urol 2009;19:595-600
87. Venkateswarlu K, Giraldi A, Zhao W, et al. Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J Urol 2002;168:355-361
88. So I, Chae MR, Lee SW. Gene transfer of the K(ATP) channel restores age-related erectile dysfunction in rats. BJU Int 2007;100:1154-1160
89. Goins WF, Goss JR, Chancellor MB, et al. Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther 2009;16:558-569
90. Gur S, Kadowitz PJ, Hellstrom WJ. A review of current progress in gene and stem cell therapy for erectile dysfunction. Expert Opin Biol Ther 2008;8:1521-1538
91. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997;71:4614-4625
92. Samaniego LA, Webb AL, DeLuca NA. Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995;69:5705-5715
93. Marconi P, Krisky D, Oligino T, et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996;93:11319-11320
94. Krisky DM, Marconi PC, Oligino T, et al. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 1997;4:1120-1125
95. Jiang C, Wechuck JB, Goins WF, et al. Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol 2004;78:8994-9006
96. Ozuer A, Wechuck JB, Goins WF, et al. Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng 2002;77:685-692
97. Ozuer A, Wechuck JB, Russell B, et al. Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors. Biotechnol Prog 2002;18:476-482
98. Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 2009;16:455-460
99. Wolfe D, Wechuck J, Krisky D, et al. A clinical trial of gene therapy for chronic pain. Pain Med 2009;10:1325-1330